Install
Cell & Gene Therapies
CAR‑T, CRISPR, in vivo delivery, manufacturing, and long‑term follow‑up.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Cell & Gene Therapies
EXCLUSIVE: Outrage Grows Over CDC Inaction on Chinese Biolab in California
37+ min ago (36+ words) A secret virus laboratory was discovered operating in a windowless building connected to a recycling center in a small farming town in California. Inside w... EXCLUSIVE: Outrage Grows Over CDC Inaction on Chinese Biolab in California...
Hong-Gang Wang and Jiawen Zhang (IMAGE)
7+ hour, 53+ min ago (187+ words) The team expected that blocking a protein called VPS34 would improve neuroblastoma immunotherapy by shutting down autophagy, the process cells use to recycle their own damaged parts. But, much of the benefit came from the VPS's second job, endolysosomal trafficking, or…...
How Gene Therapy and CAR T-Cell Therapy Are Changing Lives
1+ week, 1+ day ago (532+ words) For some patients, the future of medicine isn’t a pill. It’s their own cells. Two patients, one with sickle cell disease and one with a rare blood cancer, turned to The University of Kansas Cancer Center for answers. First-in-the-world therapies,…...
GC Cell starts phase 1b trial of CD5 CAR-NK therapy for T-cell lymphoma
7+ hour, 18+ min ago (208+ words) GC Biopharma subsidiary GC Cell said on the 7th it has begun a phase 1b trial of the new drug candidate "GCC2005 (CD5 CAR-NK)" for treating T-cell lymphoma. GC Cell earlier completed the phase 1a dose-escalation stage of GCC2005 and recently finished dosing the first patient…...
Could CRISPR correct CEP290 mutations in LCA10?
12+ hour, 52+ min ago (367+ words) The Problem of LCA10. When I stay up late at night and start fantasizing about all the great accomplishments humanity might reach in the future, I … Could CRISPR correct CEP290 mutations in LCA10? The Problem of LCA10.When I stay up late at night…...
NKF Innovation Fund Invests in Nephrogen to Advance One-Time Gene Editing Therapies for Kidney Disease
17+ hour, 52+ min ago (195+ words) Oct 06, 2026, 09:45 ET Investment supports advancement of a delivery platform built to solve the barrier that has kept genetic medicines out of the kidney, and a lead program in polycystic kidney disease. NEW YORK, Oct. 6, 2026 /PRNewswire/ -- The National Kidney Foundation (NKF)…...
Command Hospital Kolkata Administers India’s First Indigenous CAR-T Cell Therapy for Soldier with Leukemia
15+ hour, 44+ min ago (167+ words) Home » Indian Defence » Command Hospital Kolkata Administers India’s First Indigenous CAR-T Cell Therapy for Soldier with Leukemia Notably, NexCAR19 employs a humanised product configuration rather than relying on murine (mouse-derived) components, thereby minimizing the risk of severe neurological side effects commonly…...
Command Hospital Kolkata Administers Indigenous CAR-T Cell Therapy to Serving Soldier
16+ hour, 13+ min ago (436+ words) Home » Command Hospital Kolkata Administers Indigenous CAR-T Cell Therapy to Serving Soldier The achievement was carried out under the aegis of Eastern Command and reflects the adoption of advanced medical technology for the treatment of complex blood cancers among serving…...
Command Hospital Kolkata Gives Indigenous NexCAR19 CAR-T Therapy to Serving Soldier
16+ hour, 5+ min ago (270+ words) The treatment, carried out under the aegis of Eastern Command, is being seen as a notable step in the Armed Forces’ use of advanced medical technology to treat complex blood cancers among serving personnel. It also adds to the range…...
Command Hospital Kolkata administers indigenous CAR-T cell therapy to soldier
1+ day, 1+ hour ago (315+ words) The data is protected. Access granted for premium members only. For more details, please e-mail your queries to [email protected] Axis Bank A/c - 920020057946521 Command Hospital Kolkata administers indigenous CAR-T cell therapy to soldier NexCAR19, India’s first indigenous CAR-T cell therapy, has…...